Rheumatoid arthritis: emerging genetic and immunologic biomarkers

Rheumatoid arthritis (RA) is a chronic autoimmune disease in which early diagnosis and intervention are critical to prevent irreversible joint damage. While rheumatoid factor (RF) and anti-citrullinated protein antibodies (ACPA) remain diagnostic cornerstones, their limitations in sensitivity, particularly in early and seronegative RA, underscore the urgent need for novel biomarkers. This review synthesizes recent advances in the discovery of immunologic, genetic, and heterogeneous biomarkers for RA, evaluating the diagnostic and prognostic potential of a broad spectrum of candidates, including cytokines (e.g., IL-6, IL-17, IL-37), non-coding RNAs (microRNAs, long non-coding RNAs, circular RNAs), epigenetic markers, adipokines, and proteins such as matrix metalloproteinases. Evidence indicates that multi-analyte panels, often incorporating these novel biomarkers, can significantly outperform traditional serological tests. The integration of these innovative biomarkers into clinical practice holds promise for transforming RA management by enabling earlier, more precise diagnosis, improving patient stratification, and facilitating personalized treatment strategies to enhance long-term outcomes.